Stock Earnings

Question 1

Takeda Pharmaceutical Co Ltd'in temel mali tabloları nelerdir?

Accepted Answer

Son mali tabloya (Form-10K) göre, Takeda Pharmaceutical Co Ltd'in toplam varlıkları $14,248,344 olup, net profit $107,928'dir.

Question 2

TAK'ün temel finansal oranları nelerdir?

Accepted Answer

Takeda Pharmaceutical Co Ltd'in cari oranı 1.94, net kâr marjı 2.35, hisse başına satış $2,901.78'dir.

Question 3

Takeda Pharmaceutical Co Ltd'in geliri segment veya coğrafya bazında nasıl dağılıyor?

Accepted Answer

Takeda Pharmaceutical Co Ltd largest revenue segment is Gastroenterology Revenue (Pre-FY2023 Reporting), at a revenue of 1,216,207,000,000 in the most earnings release.For geography, Japan is the primary market for Takeda Pharmaceutical Co Ltd, at a revenue of 418,462,000,000.

Question 4

Takeda Pharmaceutical Co Ltd kârlı mı?

Accepted Answer

yes, son mali tablolara göre Takeda Pharmaceutical Co Ltd'in net profit $107,928'dir.

Question 5

Takeda Pharmaceutical Co Ltd'in herhangi bir yükümlülüğü var mı?

Accepted Answer

yes, Takeda Pharmaceutical Co Ltd'in yükümlülüğü 7,313,260'dir.

Question 6

Takeda Pharmaceutical Co Ltd'in tedavüldeki hisse sayısı kaçtır?

Accepted Answer

Takeda Pharmaceutical Co Ltd'in toplam tedavüldeki hisse sayısı 1,573.64'dir.

Breakdown	TTM	03/31/2025	03/31/2024	03/31/2023	03/31/2022	03/31/2021
Revenue	4,417,004	4,581,551	4,263,762	4,027,478	3,569,006	3,197,812
Revenue Growth (YoY)	-3%	7%	6%	13%	12%	-3%
Cost of Revenue	1,563,688	1,580,217	1,426,678	1,244,072	1,106,846	994,308
Gross Profit	2,853,316	3,001,334	2,837,084	2,783,406	2,462,160	2,203,504
Selling, General & Admin	1,075,890	1,104,766	1,053,819	997,309	886,361	875,663
Research & Development	691,573	730,227	729,924	633,325	526,087	455,833
Operating Expenses	2,479,739	2,464,303	2,406,297	2,232,511	1,916,672	1,867,782
Other Non Operating Income (Expenses)	1	0	1	--	1	--
Pretax Income	97,912	175,084	52,791	375,090	302,571	366,235
Income Tax Expense	64,625	66,941	-91,406	58,052	72,405	-9,936
Net Income	33,075	107,928	144,067	317,017	230,059	376,005
Net Income Growth	-89%	-25%	-55%	38%	-39%	750%
Shares Outstanding (Diluted)	1,577.46	1,578.87	1,564.45	1,569.87	1,577.16	1,573.53
Shares Change (YoY)	-2%	1%	0%	0%	0%	0%
EPS (Diluted)	20.96	68.35	92.08	201.93	145.86	238.95
EPS Growth	-88%	-26%	-54%	38%	-39%	746%
Free Cash Flow	922,298	709,341	235,614	343,467	937,068	774,463
Free Cash Flow Per Share	584.67	449.27	150.6	218.78	594.14	492.17
Gross Margin	64.59%	65.5%	66.53%	69.11%	68.98%	68.9%
Operating Margin	8.45%	11.72%	10.1%	13.67%	15.28%	10.49%
Profit Margin	0.74%	2.35%	3.37%	7.87%	6.44%	11.75%
Free Cash Flow Margin	20.88%	15.48%	5.52%	8.52%	26.25%	24.21%
EBITDA	920,352	1,100,500	952,312	1,093,338	1,018,403	757,586
EBITDA Margin	20.83%	24.02%	22.33%	27.14%	28.53%	23.69%
D&A For EBITDA	546,775	563,469	521,525	542,443	472,915	421,864
EBIT	373,577	537,031	430,787	550,895	545,488	335,722
EBIT Margin	8.45%	11.72%	10.1%	13.67%	15.28%	10.49%
Effective Tax Rate	66%	38.23%	-173.14%	15.47%	23.92%	-2.71%

Takeda Pharmaceutical Co Ltd (TAK) Price

TAK Stock Price Chart

TAK Income

Follow-Up Questions